The Manning Fund for COVID-19 Research is an innovation fund co-managed by the Provost and the VPR offices to support research focused on testing, therapies, vaccines, and ways to reopen society. The intent of this fund is to support practically oriented research on COVID-19 related topics that can be acted upon and/or preferably has a commercialization potential.
- Examples of desirable outcomes include improved diagnosis and treatment of disease through new medical devices, biomarkers for diagnostics, therapeutic targets and agents, new clinical adoption of existing tools, and innovative tools for the reopening of society.
- Although not required, it is anticipated that most projects will result in new intellectual property, commercial partnerships, or lead to start-ups.
- Target size of grant: up to $100k per project. Strong budget justification is required.
- Duration: One year maximum from start to submission of the final report. Reallocation of unspent funds are not allowed.
- Proposals will be evaluated based on its intellectual merit, practicality/viability, societal impact, commercialization potential, and qualifications of the researcher/team.
This new research catalyst fund is made possible by a $1 million commitment from local businessman and investor Paul Manning, a longtime supporter of the University and its research initiatives.
Have a question? Contact:
Cheryl Wagner cheryl-vpr@virginia.edu | 434.243.1100